DY
NAUT icon

Dowling & Yahnke’s Nautilus Biotechnolgy NAUT Stock Holding History

Dowling & Yahnke’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-45,350
Closed -$235K – 386
2021
Q4 		$235K Buy
+45,350
New +$243K 0.01% 353

Other funds holding NAUT

AEPBI
AH Equity Partners Bio II Menlo Park, California $144M AUM 54.61% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $329M AUM 64.12% 1-Year Est. Return
Amazon.com Inc
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return
AEPLI
AH Equity Partners LSV II Menlo Park, California $95.6M AUM 8.86% 1-Year Est. Return

Dowling & Yahnke's NAUT Position: Q1 2022 in Review

Dowling & Yahnke sold out of Nautilus Biotechnolgy (NAUT) in Q1 2022, closing a stake of 45,350 shares — an estimated $235K sold.

Dowling & Yahnke first reported a position in NAUT in Q4 2021 and held it in 1 quarter. The position peaked at $235K in Q4 2021. 82 funds tracked by Wall St. Rank hold NAUT as of Q1 2022.

  • Dowling & Yahnke reported no remaining Nautilus Biotechnolgy position as of Q1 2022 after selling out during the quarter.
  • Dowling & Yahnke sold 45,350 Nautilus Biotechnolgy shares in Q1 2022, an estimated $235K.
  • Dowling & Yahnke first reported a position in Nautilus Biotechnolgy in Q4 2021 and held it in 1 quarter.
  • Dowling & Yahnke's Nautilus Biotechnolgy position peaked at $235K in Q4 2021.
  • 82 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q1 2022.

Based on Dowling & Yahnke's 13F filing for Q1 2022, filed 4 May 2022.